| DB ID | MyCo_1580 |
| Title | Antibody specific to thioredoxin reductase as a new biomarker for serodiagnosis of invasive aspergillosis in non-neutropenic patients |
| Year | 2012 |
| PMID | 22366166 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The study protocol was approved by the Ethics Committee of the Jinling Hospital, Nanjing, China and informed consent was obtained fromall patients included in the study. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Animal |
| Host Common name | Rabbit |
| Host Scientific name | Oryctolagus cuniculus |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomann |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | Forty-2 non-neutropenic patients with culture- and/or histologydocumented IA were selected retrospectively between March 2008 and December 2010 from Jinling Hospital, Nanjing, China with the following diagnoses: 22 with COPD and other chronic lung diseases, 6 with chronic kidney diseases, 1 with diabetes mellitus, 1 with cirrhosis, 1 with dermatomyositis, 1 with multiorgan dysfunction syndrome, 1 with amyloidosis, 3 following near-drowning, and 6 previously healthy patients. Serum samples within the duration of the hospital stay were collected, and a total of 160 serumsamples were obtained. The average number of serum samples per patient was 3.80±2.84 (range, 2 to 11). Patients were classified as having proven or probable IA based on the standardized Invasive Fungal Infections Group of the European Organization for the Research and Treatment of Cancer Mycoses Study Group case definitions, with the modification that COPD, cirrhosis and near-drowning were added to the host factor section. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.523 |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | In recent decades, a rising incidence of invasive aspergillosis (IA) has been reported in non-neutropenic patients, even in the absence of an apparent predisposing immunodeficiency. From 0.3% to as many as 5.8% of non-neutropenic patients could be affected by this infection. The overall mortality rate in those patients with IA exceeds 80%. Several autopsy studies from non-neutropenic patients also confirm that invasive fungal infections are among the most common missed diagnoses. Patients with chronic obstructive pulmonary disease (COPD), cirrhosis, prolonged use of steroids, chronic renal failure, near-drowning or diabetes mellitus are especially at risk. Of all the Aspergillus spp., Aspergillus fumigatus is known to be the most common opportunistic pathogen that causes life-threatening IA in humans. Early diagnosis is very important because rapid initiation of appropriate antifungal therapy reduces mortality. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (the Platelia Aspergillus assay Bio-Rad) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
